Maureen Testoni, the stalwart president and CEO of the renowned 340B Health Program, will join the long-running Monitor Mondays to discuss Eli Lilly’s escalating demands for hospitals to submit in-house claims data as a condition of receiving 340B drug discounts. Who will blink first? Register now to reserve your participation. Broadcast segments will also include these instantly recognizable features: · Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds. · The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors. · Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson &amp; Byron, will join the broadcast with his trademark segment. · Legislative Update: Folana Houston, legislative affairs analyst for Zelis, will report on current healthcare legislation.

Who will Blink First? 340B Health at Center Stage as Controversy Continues

Monitor Mondays

This program is brought to you by Panacea, MedLearn Media, and First Healthcare Compliance. One organization providing education, compliance, auditing, and support services for healthcare organizations nationwide. From the studios of RAC Monitor, this is Monitor Monday for June 15, 2026. Here's today's rundown.

Beleaguered 340B Health is coming to a showdown with a major drug manufacturer. Who will be the first to blink? Providing today's lead story is the president and CEO for 340B Health, Maureen Testoni. We will also hear from healthcare attorneys David Glaser and Nicole Emanuel. Adam Brenman has our Monday legislative update, and Dr. Ronald Hirsch makes his Monday rounds. Now here's the publisher of RAC Monitor and the host of Monitor Monday, Chuck Buck.

As we come on the air this morning, we're monitoring actions of the White House, even though President Trump has left Washington to attend the G-Summit meeting taking place in France. It's been reported that the Trump administration is floating a proposal to establish a permanent framework for the Medicare drug pricing negotiations as enabled by the Inflation Reduction Act. We'll have more on this developing story when the president and CEO for 340B Health, Maureen Testoni, joins us later in the broadcast.

We have a great deal of healthcare news report, and so we begin this morning with our good friend, Ronald Hirsch. Monday Rounds is sponsored by R1 Position Advisory Solutions. Here now making his Monday rounds is Dr. Ronald Hirsch. Well, good morning all. Today I have three OIG reports to discuss, but first an update on the WISER program. Once again, it appears Congress is not happy with CMS's program to pay AI companies to use their tools

Who will Blink First? 340B Health at Center Stage as Controversy Continues

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Who will Blink First? 340B Health at Center Stage as Controversy Continues

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.